Cure My Disease

Don't miss your cure!

 Log in / Sign up

HHT drug trial pulled before it even started

NCT ID NCT07255846

Disease control Sponsor: Terremoto Biosciences Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This was a planned early-stage study of a new drug called TER-1754 for people with hereditary hemorrhagic telangiectasia (HHT), a condition that causes frequent nosebleeds and abnormal blood vessels. The trial aimed to test safety and find the right dose, but it was withdrawn before any participants were enrolled. No results are available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
TER-1754 (an AKT1 inhibitor)
What this could lead to
If this drug works, it could reduce nosebleeds and other bleeding symptoms in people with HHT, potentially improving daily life.
What could go wrong
This trial was withdrawn before enrolling any participants, so no data exists yet. As an early-phase study, safety and effectiveness are unknown, and many drug candidates fail at this stage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Started

Dec 2025

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Able to provide a signed and dated written informed consent prior to any study-specific procedures, sampling, or data collection. * A clinical diagnosis of HHT as defined by the Curaçao criteria * Baseline (1-month) ESS ≥ 4 * ECOG ≤ 2 * Anemia or parental iron infusion of at least 500 mg or transfusion of at least 2 units of RBCs within the preceding 24 weeks. * Adequate bone marrow function * Adequate renal function * Adequate hepatic function Exclusion Criteria: * Prior nonresponse or loss of response to an agent that inhibits AKT1 and/or AKT2 as the primary mechanism of action. * Diagnosis of DM requiring insulin treatment * Known significant bleeding sources other than nasal, GI, or menstrual/ uterine * Known underlying hypoproliferative anemia or clinically significant hemolytic anemia

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hereditary hemorrhagic telangiectasia (HHT) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anemia arteriovenous hemangioma/malformation Epistaxis hereditary hemorrhagic telangiectasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hereditary hemorrhagic telangiectasia (HHT)

Contacts and locations

Locations

  • Innovative Hematology, Inc.

    Indianapolis, Indiana, 46260, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.